01
Cash & equivalents increased 97.9%
Cash & equivalents changed +97.9% from the comparable as-filed period.
$22.3M→$44.2MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTUnicycive Therapeutics, Inc.'s latest supported as-filed period reports revenue of $675,000. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +97.9% from the comparable as-filed period.
Net income changed +73.3% from the comparable as-filed period.
Operating income changed -45.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
UNCY · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-088061SEC ↗10-QAug 12, 2026Period Jun 30, 20260001213900-26-088013SEC ↗4/AJul 28, 2026Period May 14, 20260001213900-26-082273SEC ↗4/AJul 28, 2026Period May 14, 20260001213900-26-082270SEC ↗8-KJul 2, 2026Period Jul 2, 20260001213900-26-074678SEC ↗8-KJun 22, 2026Period Jun 19, 20260001213900-26-070316SEC ↗4/AJun 15, 2026Period May 14, 20260001213900-26-068922SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| May 14, 2026Filed Jul 28, 2026 | Kenkare-Mitra SaraDirector | Grant Or AwardDirect · amended | 47,941 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +59.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +404.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001213900-26-068921